Stocks of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded higher last session on Wall Street, up 4.04% to $2.32.
According to the data, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) has 3 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $6.00, we find $8.00. Given the previous closing price of $2.23, this indicates a potential upside of 258.74 percent. LXRX stock price is now 9.57% away from the 50-day moving average and 2.34% away from the 200-day moving average. The market capitalization of the company currently stands at $424.88M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 1 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
With the price target of $10, Piper Sandler recently initiated with Overweight rating for Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). On January 29, 2021, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $7, while ‘Wedbush’ rates the stock as ‘Neutral’.
In other news, Artal International S.C.A., Director bought 16,173,800 shares of the company’s stock on Aug 01. The stock was bought for $40,434,500 at an average price of $2.50. Upon completion of the transaction, the Director now directly owns 48,433,261 shares in the company, valued at $112.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 01, Director Invus US Partners LLC bought 982,600 shares of the business’s stock. A total of $2,456,500 was incurred on buying the stock at an average price of $2.50. This leaves the insider owning 5,303,814 shares of the company worth $12.3 million. Insiders disposed of 133,480 shares of company stock worth roughly $0.31 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LXRX stock. A new stake in Lexicon Pharmaceuticals Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $8,383,000. RENAISSANCE TECHNOLOGIES LLC invested $1,117,000 in shares of LXRX during the first quarter. In the first quarter, CLARIVEST ASSET MANAGEMENT LLC acquired a new stake in Lexicon Pharmaceuticals Inc. valued at approximately $911,000. AQR CAPITAL MANAGEMENT LLC acquired a new stake in LXRX for approximately $697,000. NATIXIS ADVISORS, L.P. purchased a new stake in LXRX valued at around $205,000 in the second quarter. In total, there are 138 active investors with 82.30% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $2.2000 for Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). During the past 12 months, Lexicon Pharmaceuticals Inc. has had a low of $1.31 and a high of $3.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.50, and a quick ratio of 7.50. The fifty day moving average price for LXRX is $2.1222 and a two-hundred day moving average price translates $2.2673 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.16, inline with analysts’ expectations of -$0.16. This compares to -$0.16 EPS in the same period last year. The company reported revenue of $39000.0 for the quarter, compared to $23000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 69.57 percent. For the current quarter, analysts expect LXRX to generate $50k in revenue.
Lexicon Pharmaceuticals Inc.(LXRX) Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
